Global RNAi for Therapeutic Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Page: 108
Published Date: 13 Jan 2025
Category: Medical Care
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global RNAi for Therapeutic market size was valued at US$ 369 million in 2024 and is forecast to a readjusted size of USD 4213 million by 2031 with a CAGR of 42.1% during review period.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
This report is a detailed and comprehensive analysis for global RNAi for Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global RNAi for Therapeutic market size and forecasts, in consumption value ($ Million), 2020-2031
Global RNAi for Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global RNAi for Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global RNAi for Therapeutic market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for RNAi for Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global RNAi for Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Silence Therapeutics, Benitec Biopharma, miRagen Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
RNAi for Therapeutic market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
siRNA
miRNA
shRNA
Market segment by Application
Cancer
Cardiovascular
HBV
Others
Market segment by players, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin, and global market share of RNAi for Therapeutic from 2020 to 2025.
Chapter 3, the RNAi for Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and RNAi for Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNAi for Therapeutic.
Chapter 13, to describe RNAi for Therapeutic research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNAi for Therapeutic by Type
1.3.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global RNAi for Therapeutic Consumption Value Market Share by Type in 2024
1.3.3 siRNA
1.3.4 miRNA
1.3.5 shRNA
1.4 Global RNAi for Therapeutic Market by Application
1.4.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Cancer
1.4.3 Cardiovascular
1.4.4 HBV
1.4.5 Others
1.5 Global RNAi for Therapeutic Market Size & Forecast
1.6 Global RNAi for Therapeutic Market Size and Forecast by Region
1.6.1 Global RNAi for Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global RNAi for Therapeutic Market Size by Region, (2020-2031)
1.6.3 North America RNAi for Therapeutic Market Size and Prospect (2020-2031)
1.6.4 Europe RNAi for Therapeutic Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2020-2031)
1.6.6 South America RNAi for Therapeutic Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa RNAi for Therapeutic Market Size and Prospect (2020-2031)
2.1 Alnylam Pharmaceuticals
2.1.1 Alnylam Pharmaceuticals Details
2.1.2 Alnylam Pharmaceuticals Major Business
2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.2 Arbutus Biopharma (Tekmira)
2.2.1 Arbutus Biopharma (Tekmira) Details
2.2.2 Arbutus Biopharma (Tekmira) Major Business
2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
2.3 Arrowhead
2.3.1 Arrowhead Details
2.3.2 Arrowhead Major Business
2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions
2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Arrowhead Recent Developments and Future Plans
2.4 Dicerna Pharmaceuticals
2.4.1 Dicerna Pharmaceuticals Details
2.4.2 Dicerna Pharmaceuticals Major Business
2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
2.5 Mirna Therapeutics
2.5.1 Mirna Therapeutics Details
2.5.2 Mirna Therapeutics Major Business
2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions
2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Mirna Therapeutics Recent Developments and Future Plans
2.6 Quark Pharmaceuticals
2.6.1 Quark Pharmaceuticals Details
2.6.2 Quark Pharmaceuticals Major Business
2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans
2.7 RXi Pharmaceuticals
2.7.1 RXi Pharmaceuticals Details
2.7.2 RXi Pharmaceuticals Major Business
2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans
2.8 Silence Therapeutics
2.8.1 Silence Therapeutics Details
2.8.2 Silence Therapeutics Major Business
2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions
2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Silence Therapeutics Recent Developments and Future Plans
2.9 Benitec Biopharma
2.9.1 Benitec Biopharma Details
2.9.2 Benitec Biopharma Major Business
2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions
2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Benitec Biopharma Recent Developments and Future Plans
2.10 miRagen Therapeutics
2.10.1 miRagen Therapeutics Details
2.10.2 miRagen Therapeutics Major Business
2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions
2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 miRagen Therapeutics Recent Developments and Future Plans
2.11 Sylentis
2.11.1 Sylentis Details
2.11.2 Sylentis Major Business
2.11.3 Sylentis RNAi for Therapeutic Product and Solutions
2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Sylentis Recent Developments and Future Plans
2.12 Gradalis
2.12.1 Gradalis Details
2.12.2 Gradalis Major Business
2.12.3 Gradalis RNAi for Therapeutic Product and Solutions
2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Gradalis Recent Developments and Future Plans
2.13 Sirnaomics
2.13.1 Sirnaomics Details
2.13.2 Sirnaomics Major Business
2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions
2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Sirnaomics Recent Developments and Future Plans
2.14 Silenseed
2.14.1 Silenseed Details
2.14.2 Silenseed Major Business
2.14.3 Silenseed RNAi for Therapeutic Product and Solutions
2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Silenseed Recent Developments and Future Plans
3.1 Global RNAi for Therapeutic Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of RNAi for Therapeutic by Company Revenue
3.2.2 Top 3 RNAi for Therapeutic Players Market Share in 2024
3.2.3 Top 6 RNAi for Therapeutic Players Market Share in 2024
3.3 RNAi for Therapeutic Market: Overall Company Footprint Analysis
3.3.1 RNAi for Therapeutic Market: Region Footprint
3.3.2 RNAi for Therapeutic Market: Company Product Type Footprint
3.3.3 RNAi for Therapeutic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global RNAi for Therapeutic Consumption Value and Market Share by Type (2020-2025)
4.2 Global RNAi for Therapeutic Market Forecast by Type (2026-2031)
5.1 Global RNAi for Therapeutic Consumption Value Market Share by Application (2020-2025)
5.2 Global RNAi for Therapeutic Market Forecast by Application (2026-2031)
6.1 North America RNAi for Therapeutic Consumption Value by Type (2020-2031)
6.2 North America RNAi for Therapeutic Market Size by Application (2020-2031)
6.3 North America RNAi for Therapeutic Market Size by Country
6.3.1 North America RNAi for Therapeutic Consumption Value by Country (2020-2031)
6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2020-2031)
6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2020-2031)
6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2020-2031)
7.1 Europe RNAi for Therapeutic Consumption Value by Type (2020-2031)
7.2 Europe RNAi for Therapeutic Consumption Value by Application (2020-2031)
7.3 Europe RNAi for Therapeutic Market Size by Country
7.3.1 Europe RNAi for Therapeutic Consumption Value by Country (2020-2031)
7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2020-2031)
7.3.3 France RNAi for Therapeutic Market Size and Forecast (2020-2031)
7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2020-2031)
7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2020-2031)
7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2020-2031)
8.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2020-2031)
8.2 Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2020-2031)
8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region
8.3.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2020-2031)
8.3.2 China RNAi for Therapeutic Market Size and Forecast (2020-2031)
8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2020-2031)
8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2020-2031)
8.3.5 India RNAi for Therapeutic Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2020-2031)
8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2020-2031)
9.1 South America RNAi for Therapeutic Consumption Value by Type (2020-2031)
9.2 South America RNAi for Therapeutic Consumption Value by Application (2020-2031)
9.3 South America RNAi for Therapeutic Market Size by Country
9.3.1 South America RNAi for Therapeutic Consumption Value by Country (2020-2031)
9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2020-2031)
9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2020-2031)
10.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2020-2031)
10.2 Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2020-2031)
10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country
10.3.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2020-2031)
10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2020-2031)
10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2020-2031)
11.1 RNAi for Therapeutic Market Drivers
11.2 RNAi for Therapeutic Market Restraints
11.3 RNAi for Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12.1 RNAi for Therapeutic Industry Chain
12.2 RNAi for Therapeutic Upstream Analysis
12.3 RNAi for Therapeutic Midstream Analysis
12.4 RNAi for Therapeutic Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global RNAi for Therapeutic Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global RNAi for Therapeutic Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global RNAi for Therapeutic Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 6. Alnylam Pharmaceuticals Major Business
Table 7. Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 8. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Alnylam Pharmaceuticals Recent Developments and Future Plans
Table 10. Arbutus Biopharma (Tekmira) Company Information, Head Office, and Major Competitors
Table 11. Arbutus Biopharma (Tekmira) Major Business
Table 12. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
Table 13. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
Table 15. Arrowhead Company Information, Head Office, and Major Competitors
Table 16. Arrowhead Major Business
Table 17. Arrowhead RNAi for Therapeutic Product and Solutions
Table 18. Arrowhead RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Dicerna Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 20. Dicerna Pharmaceuticals Major Business
Table 21. Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 22. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Dicerna Pharmaceuticals Recent Developments and Future Plans
Table 24. Mirna Therapeutics Company Information, Head Office, and Major Competitors
Table 25. Mirna Therapeutics Major Business
Table 26. Mirna Therapeutics RNAi for Therapeutic Product and Solutions
Table 27. Mirna Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Mirna Therapeutics Recent Developments and Future Plans
Table 29. Quark Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 30. Quark Pharmaceuticals Major Business
Table 31. Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 32. Quark Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Quark Pharmaceuticals Recent Developments and Future Plans
Table 34. RXi Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 35. RXi Pharmaceuticals Major Business
Table 36. RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 37. RXi Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. RXi Pharmaceuticals Recent Developments and Future Plans
Table 39. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 40. Silence Therapeutics Major Business
Table 41. Silence Therapeutics RNAi for Therapeutic Product and Solutions
Table 42. Silence Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Silence Therapeutics Recent Developments and Future Plans
Table 44. Benitec Biopharma Company Information, Head Office, and Major Competitors
Table 45. Benitec Biopharma Major Business
Table 46. Benitec Biopharma RNAi for Therapeutic Product and Solutions
Table 47. Benitec Biopharma RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Benitec Biopharma Recent Developments and Future Plans
Table 49. miRagen Therapeutics Company Information, Head Office, and Major Competitors
Table 50. miRagen Therapeutics Major Business
Table 51. miRagen Therapeutics RNAi for Therapeutic Product and Solutions
Table 52. miRagen Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. miRagen Therapeutics Recent Developments and Future Plans
Table 54. Sylentis Company Information, Head Office, and Major Competitors
Table 55. Sylentis Major Business
Table 56. Sylentis RNAi for Therapeutic Product and Solutions
Table 57. Sylentis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Sylentis Recent Developments and Future Plans
Table 59. Gradalis Company Information, Head Office, and Major Competitors
Table 60. Gradalis Major Business
Table 61. Gradalis RNAi for Therapeutic Product and Solutions
Table 62. Gradalis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Gradalis Recent Developments and Future Plans
Table 64. Sirnaomics Company Information, Head Office, and Major Competitors
Table 65. Sirnaomics Major Business
Table 66. Sirnaomics RNAi for Therapeutic Product and Solutions
Table 67. Sirnaomics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Sirnaomics Recent Developments and Future Plans
Table 69. Silenseed Company Information, Head Office, and Major Competitors
Table 70. Silenseed Major Business
Table 71. Silenseed RNAi for Therapeutic Product and Solutions
Table 72. Silenseed RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. Silenseed Recent Developments and Future Plans
Table 74. Global RNAi for Therapeutic Revenue (USD Million) by Players (2020-2025)
Table 75. Global RNAi for Therapeutic Revenue Share by Players (2020-2025)
Table 76. Breakdown of RNAi for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 77. Market Position of Players in RNAi for Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 78. Head Office of Key RNAi for Therapeutic Players
Table 79. RNAi for Therapeutic Market: Company Product Type Footprint
Table 80. RNAi for Therapeutic Market: Company Product Application Footprint
Table 81. RNAi for Therapeutic New Market Entrants and Barriers to Market Entry
Table 82. RNAi for Therapeutic Mergers, Acquisition, Agreements, and Collaborations
Table 83. Global RNAi for Therapeutic Consumption Value (USD Million) by Type (2020-2025)
Table 84. Global RNAi for Therapeutic Consumption Value Share by Type (2020-2025)
Table 85. Global RNAi for Therapeutic Consumption Value Forecast by Type (2026-2031)
Table 86. Global RNAi for Therapeutic Consumption Value by Application (2020-2025)
Table 87. Global RNAi for Therapeutic Consumption Value Forecast by Application (2026-2031)
Table 88. North America RNAi for Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 89. North America RNAi for Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 90. North America RNAi for Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 91. North America RNAi for Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 92. North America RNAi for Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 93. North America RNAi for Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 94. Europe RNAi for Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 95. Europe RNAi for Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 96. Europe RNAi for Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 97. Europe RNAi for Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 98. Europe RNAi for Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 99. Europe RNAi for Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 100. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 101. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 102. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 103. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 104. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2020-2025) & (USD Million)
Table 105. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2026-2031) & (USD Million)
Table 106. South America RNAi for Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 107. South America RNAi for Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 108. South America RNAi for Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 109. South America RNAi for Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 110. South America RNAi for Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 111. South America RNAi for Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 112. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 113. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 114. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 115. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 116. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 117. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 118. Global Key Players of RNAi for Therapeutic Upstream (Raw Materials)
Table 119. Global RNAi for Therapeutic Typical Customers
List of Figures
Figure 1. RNAi for Therapeutic Picture
Figure 2. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global RNAi for Therapeutic Consumption Value Market Share by Type in 2024
Figure 4. siRNA
Figure 5. miRNA
Figure 6. shRNA
Figure 7. Global RNAi for Therapeutic Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 8. RNAi for Therapeutic Consumption Value Market Share by Application in 2024
Figure 9. Cancer Picture
Figure 10. Cardiovascular Picture
Figure 11. HBV Picture
Figure 12. Others Picture
Figure 13. Global RNAi for Therapeutic Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global RNAi for Therapeutic Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Market RNAi for Therapeutic Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 16. Global RNAi for Therapeutic Consumption Value Market Share by Region (2020-2031)
Figure 17. Global RNAi for Therapeutic Consumption Value Market Share by Region in 2024
Figure 18. North America RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 20. Asia-Pacific RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 21. South America RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 22. Middle East & Africa RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global RNAi for Therapeutic Revenue Share by Players in 2024
Figure 25. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 26. Market Share of RNAi for Therapeutic by Player Revenue in 2024
Figure 27. Top 3 RNAi for Therapeutic Players Market Share in 2024
Figure 28. Top 6 RNAi for Therapeutic Players Market Share in 2024
Figure 29. Global RNAi for Therapeutic Consumption Value Share by Type (2020-2025)
Figure 30. Global RNAi for Therapeutic Market Share Forecast by Type (2026-2031)
Figure 31. Global RNAi for Therapeutic Consumption Value Share by Application (2020-2025)
Figure 32. Global RNAi for Therapeutic Market Share Forecast by Application (2026-2031)
Figure 33. North America RNAi for Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 34. North America RNAi for Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 35. North America RNAi for Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 36. United States RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 37. Canada RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 38. Mexico RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 39. Europe RNAi for Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 40. Europe RNAi for Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 41. Europe RNAi for Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 42. Germany RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 43. France RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 44. United Kingdom RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 45. Russia RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 46. Italy RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 47. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 48. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 49. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Region (2020-2031)
Figure 50. China RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 51. Japan RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 52. South Korea RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 53. India RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 54. Southeast Asia RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 55. Australia RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 56. South America RNAi for Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 57. South America RNAi for Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 58. South America RNAi for Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 59. Brazil RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 60. Argentina RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 61. Middle East & Africa RNAi for Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 62. Middle East & Africa RNAi for Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 63. Middle East & Africa RNAi for Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 64. Turkey RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 65. Saudi Arabia RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 66. UAE RNAi for Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 67. RNAi for Therapeutic Market Drivers
Figure 68. RNAi for Therapeutic Market Restraints
Figure 69. RNAi for Therapeutic Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. RNAi for Therapeutic Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Alnylam Pharmaceuticals Arbutus Biopharma (Tekmira) Arrowhead Dicerna Pharmaceuticals Mirna Therapeutics Quark Pharmaceuticals RXi Pharmaceuticals Silence Therapeutics Benitec Biopharma miRagen Therapeutics Sylentis Gradalis Sirnaomics Silenseed
Related Reports
18 Mar 2023
Medical Care
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
